Xavier Amate-Bosch

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series.

Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series.

Journal: Acta dermato-venereologica

Published: April 06, 2026

Extensive calcinosis in dermatomyositis treated with anifrolumab.

Extensive calcinosis in dermatomyositis treated with anifrolumab.

Journal: Rheumatology (Oxford, England)

Published: February 02, 2026

Anifrolumab for lupus erythematosus in real-world practice: A Spanish national series.

Anifrolumab for lupus erythematosus in real-world practice: A Spanish national series.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 03, 2026

Novel Clinical and Histological Insights into Cutaneous Kikuchi-Fujimoto Disease and Kikuchi Disease-Like Inflammatory Pattern (KLIP).

Novel Clinical and Histological Insights into Cutaneous Kikuchi-Fujimoto Disease and Kikuchi Disease-Like Inflammatory Pattern (KLIP).

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: June 24, 2025

High-Frequency Ultrasound Assessment of Skin Thickness Following Lipofilling in Facial Sclerosing Dermatoses: A Case Series.

High-Frequency Ultrasound Assessment of Skin Thickness Following Lipofilling in Facial Sclerosing Dermatoses: A Case Series.

Journal: Journal of cosmetic dermatology

Published: January 28, 2025

Anifrolumab Treatment in Cutaneous Lupus Erythematosus with and without systemic involvement: A Retrospective Study.

Anifrolumab Treatment in Cutaneous Lupus Erythematosus with and without systemic involvement: A Retrospective Study.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: January 17, 2025

Refractory Dermatomyositis Treated With Anifrolumab: Clinical Response and Dynamics of Type-I Interferon Signature.

Refractory Dermatomyositis Treated With Anifrolumab: Clinical Response and Dynamics of Type-I Interferon Signature.

Journal: Actas dermo-sifiliograficas

Published: November 28, 2024

Rheumatologic complications of CAR-T Cell therapy. Experience of a single center.

Rheumatologic complications of CAR-T Cell therapy. Experience of a single center.

Journal: Seminars in arthritis and rheumatism

Published: October 29, 2024

Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series.

Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series.

Journal: The British journal of dermatology

Published: July 08, 2024

JAK inhibitors in refractory dermatomyositis: A case series.

JAK inhibitors in refractory dermatomyositis: A case series.

Journal: The Australasian journal of dermatology

Published: January 17, 2024

Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience.

Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience.

Journal: Clinical and experimental dermatology

Published: October 09, 2023

Sweet Syndrome: Clinical Presentation, Malignancy Association, Autoinflammatory Disorders and Treatment Response in a Cohort of 93 Patients with Long-term Follow-up.

Sweet Syndrome: Clinical Presentation, Malignancy Association, Autoinflammatory Disorders and Treatment Response in a Cohort of 93 Patients with Long-term Follow-up.

Journal: Acta dermato-venereologica

Published: July 21, 2023

Showing 1-12 of 54

Last Updated: 09/26/2026